Most Recent Articles by Stan Grossman
A survey showed 67.3% of patient advocacy organizations received industry funding, while 11.9% received more than half of their funding from industry.
Katherine A. Roberts, MD, FACE, ECNU, discusses her choice to opt out of Medicare and offers advice to physicians considering doing the same.
Intrathecal dosing of neural progenitors appears to be safe and well tolerated in patients with progressive multiple sclerosis.
Investigational agent has the potential to repair damaged myelin sheath and restore function in patients with secondary-progressive multiple sclerosis.
Patients with MS were likely to experience relapses for the first time or relapse continuation between the ages of 27 and 47 years.
More Articles by Stan Grossman
Neurology Advisor Articles
- Vitamin D Deficiency Affects Cognition in Multiple Sclerosis
- Hypothalamus May Play a Central Role in Chronic Migraine
- An Interdisciplinary Approach to Advanced Parkinson's Care
- Migraine Attacks Associated With Reduced Dopamine Levels
- Polypharmacy in Schizophrenia May Have Adverse Effect on Cognition
- Alzheimer's Mortality Increasing, But So Is At-Home Care
- Special Diets, Supplements for Autism Not Backed by Solid Evidence
- In MS, Disease Duration, Lesion Load Predict Relapses and Disability Progression
- Ocrelizumab May Improve Cognitive Function in Relapsing Multiple Sclerosis
- Teriflunomide for MS Associated With Low Rates of Infection, Lymphopenia